Wire · opportunities
FDA advisory panel votes to place popular peptide TB-500 on compounding list
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
An FDA advisory panel voted to place TB-500, a popular research peptide, on the compounding list, reclassifying it from an unapproved drug to a compound available through licensed pharmacies.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 23 Jul 2026 and 24 Jul 2026.
◆ ◆ The Wire takeaway
If you're building a peptide therapy or biotech business targeting TB-500 applications (muscle recovery, wound healing, performance), compounding list placement creates a legal sales route but floods the market with cheaper compounded versions and locks you out of premium pricing until you run full FDA approval. Move fast on proprietary formulations or indications, or pivot to customers who need pharmaceutical-grade guarantees.
◆ Coverage
2 sources · first reported 23 Jul 2026 · latest 24 Jul 2026
◆ Related on Wire
◆ Topics